Back to search

Article

Neoadjuvant Combination Immunotherapy for Colorectal Cancer: Clinical and Molecular Predictors of Pathological Complete Response and Safety Assessment

2024-03-07

Abstract excerpt

<h4>Purpose: </h4> To identify the clinical and molecular factors that effectively predict pathological complete response (pCR) and assess the safety of patients receiving neoadjuvant combination immunotherapy. Materials and Methods This retrospective study evaluated 81 patients with colorectal cancer (CRC) at a Chinese tertiary center between 2015 and 2023. The cohort included 24 patients with deficient mismatch...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0ff9a2ca-5c99-5c8f-bc03-0e92391a6e79
DOI
10.21203/rs.3.rs-4001747/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Neoadjuvant Combination Immunotherapy for Colorectal Cancer: Clinical and Molecular Predictors of Pathological Complete Response and Safety AssessmentDOI 10.21203/rs.3.rs-4001747/v1
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of responseSemantic proximity
Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 studySemantic proximity
Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety.Semantic proximity
The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A Systematic Review and Meta-AnalysisSemantic proximity
Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancerSemantic proximity
A randomized, open, multicenter Phase II study to explore the sequential use of chemotherapy and immunotherapy in postoperative adjuvant therapy for gastric or esophagogastric junction adenocarcinoma or colorectal adenocarcinoma with radical resection of POLE/POLD1 gene mutation or dMMR/MSI-HSemantic proximity
Endoscopic and imaging evaluations of neoadjuvant immunotherapy in patients with locally advanced colorectal cancer with dMMR/MSI-H or POLE/POLD1 mutation.Semantic proximity
An Integrated Model of Pathological Complete Response and Postoperative CEA Predicts Survival and Benefit of Adjuvant Chemotherapy for Locally Advanced Rectal CancerSemantic proximity
Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series.Semantic proximity
Comparative Analysis of Clinical Outcomes Between Neoadjuvant Chemoimmunotherapy and Neoadjuvant Chemoradiotherapy in Patients with Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Retrospective StudySemantic proximity
Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistanceSemantic proximity
Dual-immunotherapy triumphs: redefining deficient mismatch repair or high microsatellite instability metastatic colorectal cancer first-line treatmentSemantic proximity
Select a neighboring publication to make it the new centre.